title: Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats.
abstract: Tobacco addiction is characterized by a negative mood state upon smoking cessation and relapse after periods of abstinence. Clinical studies indicate that negative mood states lead to craving and relapse. The partial α4/α6/β2* nicotinic acetylcholine receptor (nAChR) agonists varenicline and cytisine are widely used as smoking cessation treatments. Varenicline has been approved in the United States for smoking cessation and cytisine is used in Eastern European countries. Despite the widespread use of these compounds, very little is known about their effects on mood states. These studies investigated the effects of varenicline, cytisine, and the cytisine-derivative 3-(pyridin-3'-yl)-cytisine (3-pyr-Cyt) on brain reward function in nicotine-naive and nicotine-withdrawing rats. The cytisine-derivative 3-pyr-Cyt is a very weak α4β2* nAChR partial agonist and like cytisine and varenicline has antidepressant-like effects in animal models. The intracranial self-stimulation (ICSS) procedure was used to investigate the effects of these compounds on brain reward function. Elevations in ICSS thresholds reflect a dysphoric state and a lowering of thresholds is indicative of a potentiation of brain reward function. It was shown that acute administration of nicotine and varenicline lowered ICSS thresholds. Acute administration of cytisine or 3-pyr-Cyt did not affect ICSS thresholds. Discontinuation of chronic, 14 days, nicotine administration led to elevations in ICSS thresholds that lasted for about 2 days. Varenicline and cytisine, but not 3-pyr-Cyt, diminished the nicotine withdrawal-induced elevations in ICSS thresholds. In conclusion, these studies indicate that varenicline and cytisine diminish the dysphoric-like state associated with nicotine withdrawal and may thereby prevent relapse to smoking in humans.
authors: Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
authors: Moe
authors: M
authors: Igari
authors: Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
authors: Jon C
authors: JC
authors: Alexander
authors: Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
authors: Yue
authors: Y
authors: Ji
authors: Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
authors: Xiaoli
authors: X
authors: Qi
authors: Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA.
authors: Roger L
authors: RL
authors: Papke
authors: Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
authors: Adrie W
authors: AW
authors: Bruijnzeel
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage*; D000818:Animals; D001392:Azocines / Q000008:administration & dosage; D001552:Benzazepines / Q000008:administration & dosage*; D015918:Infusion Pumps, Implantable; D008297:Male; D009538:Nicotine / Q000008:administration & dosage* / Q000009:adverse effects*; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D011807:Quinolizines / Q000008:administration & dosage; D011810:Quinoxalines / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control* / Q000523:psychology; D000068580:Varenicline; D000093843:Quinolizidine Alkaloids
chemical_list: D000470:Alkaloids; D001392:Azocines; D001552:Benzazepines; D009538:Nicotine; D018722:Nicotinic Agonists; D011807:Quinolizines; D011810:Quinoxalines; D000068580:Varenicline; C004712:cytisine; D000093843:Quinolizidine Alkaloids
references: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1162-3
references: 21396974
references: Am J Psychiatry. 2009 May;166(5):619-20
references: 19411384
references: Nature. 2011 Mar 31;471(7340):597-601
references: 21278726
references: Nat Rev Neurosci. 2010 Jun;11(6):389-401
references: 20485364
references: J Pharmacol Exp Ther. 2010 May;333(2):501-18
references: 20100906
references: Am J Psychiatry. 2010 Jun;167(6):720-1
references: 20516169
references: Neuropsychopharmacology. 2007 Apr;32(4):955-63
references: 16943772
references: Mol Pharmacol. 2012 Apr;81(4):541-8
references: 22222765
references: Arch Intern Med. 2006 Aug 14-28;166(15):1553-9
references: 16908787
references: N Engl J Med. 2011 Sep 29;365(13):1193-200
references: 21991893
references: J Pharmacol Exp Ther. 2011 May;337(2):367-79
references: 21285282
references: Biol Psychiatry. 2003 Jul 1;54(1):49-58
references: 12842308
references: Pharmacol Biochem Behav. 2009 Jan;91(3):461-7
references: 18817808
references: Gen Hosp Psychiatry. 2011 Nov-Dec;33(6):641.e1-2
references: 21749843
references: Naunyn Schmiedebergs Arch Pharmacol. 2010 Apr;381(4):361-70
references: 20217050
references: Annu Rev Pharmacol Toxicol. 2007;47:699-729
references: 17009926
references: Psychoneuroendocrinology. 2003 Oct;28(7):916-31
references: 12892658
references: Neuropsychopharmacology. 2009 Jan;34(2):266-81
references: 18418357
references: Mol Pharmacol. 2004 Jun;65(6):1526-35
references: 15155845
references: Cochrane Database Syst Rev. 2004;(3):CD000058
references: 15266422
references: Psychopharmacology (Berl). 1984;84(3):413-9
references: 6440189
references: J Pharmacol Exp Ther. 2009 Apr;329(1):377-86
references: 19164465
references: J Pharmacol Exp Ther. 2000 Oct;295(1):321-7
references: 10991997
references: J Med Chem. 2005 May 19;48(10):3474-7
references: 15887955
references: Mol Pharmacol. 2013 Apr;83(4):753-8
references: 23247824
references: Trends Pharmacol Sci. 2002 Oct;23(10):475-82
references: 12368072
references: Pharmacol Biochem Behav. 1985 Feb;22(2):237-41
references: 2858867
references: Psychopharmacology (Berl). 1995 Jan;117(1):2-10; discussion 14-20
references: 7724697
references: Int J Geriatr Psychiatry. 2011 Jun;26(6):658-9
references: 21480382
references: Pharmacol Biochem Behav. 1994 Jun;48(2):521-4
references: 8090825
references: Pharmacol Biochem Behav. 1998 Jun;60(2):567-73
references: 9632242
references: Neuropharmacology. 2013 Jul;70:228-35
references: 23416040
references: Br J Pharmacol. 2010 May;160(2):334-45
references: 20331614
references: Psychopharmacology (Berl). 2002 Feb;160(1):56-66
references: 11862374
references: Neuropsychopharmacology. 2010 Jan;35(1):217-38
references: 19710631
references: J Pharm Sci. 2003 May;92(5):1051-7
references: 12712425
references: Clin Pharmacol Ther. 2008 Apr;83(4):607-14
references: 18288085
references: Nicotine Tob Res. 2001 Nov;3(4):361-73
references: 11694204
references: Neuropharmacology. 2012 Sep;63(4):538-46
references: 22580377
references: Arch Gen Psychiatry. 1979 Mar;36(3):289-92
references: 420547
references: Clin Neuropharmacol. 2009 Mar-Apr;32(2):117-8
references: 19512966
references: Neuropsychopharmacology. 2009 Jun;34(7):1743-52
references: 19145226
references: Life Sci. 1994;55(15):1179-86
references: 7934614
references: Neuropharmacology. 2009 Jul;57(1):60-6
references: 19393252
references: Psychopharmacology (Berl). 2005 Apr;178(4):481-92
references: 15765262
references: J Pharmacol Exp Ther. 2012 Nov;343(2):441-50
references: 22899752
references: J Am Soc Hypertens. 2013 Jan-Feb;7(1):61-7
references: 23266101
references: Fed Proc. 1979 Oct;38(11):2473-6
references: 488370
references: Neuropharmacology. 2010 Jun;58(7):1054-66
references: 20114055
references: Drug Metab Dispos. 2006 Jan;34(1):121-30
references: 16221753
references: JAMA. 2006 Jul 5;296(1):56-63
references: 16820547
references: Pharmacol Biochem Behav. 2012 Mar;101(1):62-8
references: 22182462
references: Neurosci Biobehav Rev. 2012 May;36(5):1418-41
references: 22405889
references: Biol Psychiatry. 2009 Jul 15;66(2):110-7
references: 19217073
references: J Neurochem. 2002 Aug;82(3):468-81
references: 12153472
references: Nature. 1998 May 7;393(6680):76-9
references: 9590692
references: Physiol Behav. 1992 Jan;51(1):111-9
references: 1741436
references: Drug Metab Dispos. 1988 Nov-Dec;16(6):823-8
references: 2907460
references: Cold Spring Harb Perspect Med. 2013 Jan 01;3(1):a012112
references: 23143843
references: Trends Neurosci. 2011 Jul;34(7):383-92
references: 21696833
references: Neuropsychopharmacology. 2012 May;37(6):1367-76
references: 22278092
references: Mol Pharmacol. 2006 Sep;70(3):801-5
references: 16766716